REAL ID

Showing 4020 articles
Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Business

Heidelberg Materials Gains Momentum as Investors Bet on Green Cement Boom

Heidelberg Materials (XTRA:HEI) is attracting renewed investor interest, fueled by accelerating global demand for sustainable construction materials. The company's strategic positioning in low-carbon cement and aggregates coincides with strong shareholder returns, raising questions about its current valuation in a rapidly evolving market.

Business

Ichor Holdings: A Valuation Check After the Stock's Wild Ride

Ichor Holdings (ICHR) shares have taken investors on a rollercoaster, soaring over 64% in a month before a sharp 9% single-day drop. With the semiconductor equipment maker posting revenue near $1 billion alongside net losses, the market is grappling with how to price its future in a cyclical industry. We examine whether the pullback presents a buying opportunity or a warning sign.